The European Medicines Agency (EMA) has accepted Takeda Pharmaceutical Company Limited’s filing packages for its dengue vaccine candidate (TAK-003), which is being investigated to prevent dengue due to any dengue virus serotype in individuals ages four to 60.
Dengue is the fastest spreading mosquito-borne viral disease and was one of the World Health Organization’s leading global health risks in 2019. Dengue is estimated to cause 390 million infections and around 20,000 fatalities globally each year.
Dengue Vaccine Candidate Seeks Europe’s Approval
Race May Affect Link Between Vitamin D Level, COVID-19 Risk
Vitamin D levels less than 40 ng/mL linked to increased risk for COVID-19 positivity in Black, but not White, individuals
Remdesivir Linked to Faster Clinical Improvement of COVID-19
Findings seen in mainly non-White race/ethnicity patients hospitalized with confirmed SARS-CoV-2 infection
AstraZeneca Reports Slightly Lower Estimate of COVID-19 Vaccine Effectiveness
After saying that the vaccine was 79 percent effective on Monday, the company said Wednesday that the vaccine was 76 percent effective
White House Announces $10 Billion More to Increase COVID-19 Vaccination Rates
About $6 billion will go to community health centers to expand COVID-19 vaccinations, testing for high-risk populations
State AGs Urge Facebook, Twitter to Tackle Vaccine Misinformation
Attorneys general say ‘anti-vaxxer’ accounts on Facebook, YouTube, Instagram, and Twitter reach more than 59 million followers